Boron agents termed GluBs reach previously untreatable tumors
Researchers developed GluBs to target ASCT2 in aggressive cancers, bypassing the LAT1 route. The agents showed efficacy in limiting tumor growth and demonstrating potential to treat cancers with limited LAT1 expression.